We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Indian Sites Hit With Warning Letter Over cGMP Lapses
The item has been added to your shopping cart.
Sandoz Indian Sites Hit With Warning Letter Over cGMP Lapses
Novartis’ generics unit Sandoz received a warning letter from the FDA citing cGMP deficiencies for finished drugs at the company’s plants in Kalwe and Turbhe, India.